Abvc Biopharma (ABVC) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Abvc Biopharma (ABVC) over the last 10 years, with Q3 2025 value amounting to $0.06.
- Abvc Biopharma's Debt to Equity fell 8977.16% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.06, marking a year-over-year decrease of 8977.16%. This contributed to the annual value of $0.69 for FY2024, which is 447.79% down from last year.
- As of Q3 2025, Abvc Biopharma's Debt to Equity stood at $0.06, which was down 8977.16% from $0.09 recorded in Q2 2025.
- Abvc Biopharma's 5-year Debt to Equity high stood at $3.78 for Q2 2021, and its period low was $0.05 during Q3 2021.
- Its 5-year average for Debt to Equity is $0.51, with a median of $0.12 in 2021.
- In the last 5 years, Abvc Biopharma's Debt to Equity tumbled by 9869.34% in 2022 and then surged by 48262.09% in 2024.
- Abvc Biopharma's Debt to Equity (Quarter) stood at $0.12 in 2021, then soared by 397.48% to $0.59 in 2022, then increased by 22.59% to $0.72 in 2023, then decreased by 4.48% to $0.69 in 2024, then crashed by 91.85% to $0.06 in 2025.
- Its last three reported values are $0.06 in Q3 2025, $0.09 for Q2 2025, and $0.1 during Q1 2025.